Cargando…
Intralesional epidermal growth factor for diabetic foot wounds: the first cases in Turkey
BACKGROUND: Intralesional recombinant epidermal growth factor (EGF) was produced in the Centre for Genetic Engineering and Biotechnology (CIGB), Cuba, in 1988 and licensed in 2006. Because it may accelerate wound healing, it is a potential new treatment option in patients with a diabetic foot wound...
Autores principales: | Ertugrul, Bulent M., Buke, Cagri, Ersoy, Ozlem Saylak, Ay, Bengisu, Demirez, Dilek Senen, Savk, Oner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534624/ https://www.ncbi.nlm.nih.gov/pubmed/26268583 http://dx.doi.org/10.3402/dfa.v6.28419 |
Ejemplares similares
-
Osteomyelitis or Charcot neuro-osteoarthropathy? Differentiating these disorders in diabetic patients with a foot problem
por: Ertugrul, Bulent M., et al.
Publicado: (2013) -
The role of rehabilitation in the management of diabetic foot wounds.
por: Aydın, Elif, et al.
Publicado: (2021) -
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers
por: Yera-Alos, Isis B, et al.
Publicado: (2013) -
Wound Myiasis in Diabetic Foot Ulcer: Calliphoridae and Sarcophagidae Family
por: Tileklioğlu, Evren, et al.
Publicado: (2021) -
Intralesional Administration of Human Recombinant Epidermal Growth Factor Improves Healing and Reduces Amputations in Patients with Severe Diabetic Foot Ulcers
por: Garcia Herrera, Aristides L.
Publicado: (2017)